Teicoplanin
Trade name
Targocid, Teicoplanin (Sandoz)
Presentation and preparation
|
Vial size
(powder volume) |
Fluid to add
|
Volume to add
|
Resulting concentration
|
|---|---|---|---|
|
Targocid* |
Water for injections provided
|
3.14 mL (entire contents of diluent provided)
|
133 mg/mL
|
|
Teicoplanin (Sandoz) |
Water for injections provided
|
3 mL
|
133 mg/mL |
*Targocid vials contain a significant amount of overage: 400 mg vials contain 460 mg of teicoplanin.
Slowly add diluent towards the wall of the vial and gently rotate to wet the powder. Do not shake.
If foam develops during reconstitution, allow the vial to stand for 15 minutes before withdrawing dose.
IV administration
Give undiluted over 5 minutes or dilute to a convenient volume and give over 30 minutes.
Infusion over 30 minutes is preferred to avoid infusion-related reactions.
Neonates: Infuse over 30 minutes.
Other routes of administration
IM: Suitable. Give undiluted. Maximum of 400 mg/3 mL at a single injection site.
SC: Not recommended.
Compatible IV fluids
Glucose 5%
Hartmann’s
Sodium chloride 0.9%
Additional information
Observe closely for anaphylactic reactions.
IV aminoglycoside antibiotics are inactivated by IV cephalosporins, penicillins and teicoplanin; refer to Glossary and Notes.
Rapid administration may cause vancomycin infusion reaction (previously referred to as red man syndrome). Symptoms include rash, angioneurotic oedema, tachycardia, hypotension and dyspnoea.
If this occurs:
- cease infusion and inform medical staff
- check dosage and infusion rate
- wait for symptoms to resolve
- resume infusion at a slower rate
- report and document adverse reaction
Therapeutic Drug Monitoring may be required; refer to local guidelines.
Reconstituted solution should be clear and colourless to yellow.